Sandbox:Sara
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
- Immunhistochemical staining of dermatofibrosarcoma protuberans shows:
- ↑ West RB, Harvell J, Linn SC, Liu CL, Prapong W, Hernandez-Boussard T; et al. (2004). "Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans". Am J Surg Pathol. 28 (8): 1063–9. PMID 15252314.
- ↑ Lisovsky M, Hoang MP, Dresser KA, Kapur P, Bhawan J, Mahalingam M (2008). "Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans". Mod Pathol. 21 (1): 31–8. doi:10.1038/modpathol.3800971. PMID 17885669.
- ↑ Bandarchi B, Ma L, Marginean C, Hafezi S, Zubovits J, Rasty G (2010). "D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans". Mod Pathol. 23 (3): 434–8. doi:10.1038/modpathol.2009.176. PMID 20062007.
- ↑ Ma CK, Zarbo RJ, Gown AM (1992). "Immunohistochemical characterization of atypical fibroxanthoma and dermatofibrosarcoma protuberans". Am J Clin Pathol. 97 (4): 478–83. doi:10.1093/ajcp/97.4.478. PMID 1553911.
- ↑ Diwan AH, Skelton HG, Horenstein MG, Kelly DR, Barrett TL, Bussian AH; et al. (2008). "Dermatofibrosarcoma protuberans and giant cell fibroblastoma exhibit CD99 positivity". J Cutan Pathol. 35 (7): 647–50. doi:10.1111/j.1600-0560.2007.00872.x. PMID 18201229.
- ↑ Labonte S, Hanna W, Bandarchi-Chamkhaleh B (2007). "A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma". J Cutan Pathol. 34 (11): 857–60. doi:10.1111/j.1600-0560.2007.00731.x. PMID 17944726.